Johnson & Johnson (JNJ)

Mar 31, 2025, 4:07 PM EDT - 3 hours ago

Best Dividend Aristocrats For April 2025

ABBV ABT ADM BDX BEN BRO CAH

Mar 30, 2025, 5:52 PM EDT - 1 day ago

Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of April

PG AON AWK BBY CL COST CTRE

Mar 29, 2025, 7:00 AM EDT - 2 days ago

If I Could Only Choose 5 Dividend Stocks For My Retirement Portfolio

BLK O PEP V

Mar 28, 2025, 4:40 PM EDT - 3 days ago

Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)

Mar 28, 2025, 12:19 PM EDT - 3 days ago

Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case

Mar 27, 2025, 10:22 AM EDT - 4 days ago

Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.

ABBV AMGN BIIB BMY GILD IHE LLY

Mar 26, 2025, 6:00 PM EDT - 5 days ago

Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns

AAPL AMZN ARCC BAC BEP BHP BLK

Mar 26, 2025, 12:30 PM EDT - 5 days ago

The Big 3: JNJ, GE, LULU

GE LULU

Mar 26, 2025, 11:45 AM EDT - 5 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

Mar 26, 2025, 8:03 AM EDT - 5 days ago

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

Mar 24, 2025, 3:31 PM EDT - 7 days ago

BofA reveals stocks with a history of steady returns amid market volatility

CLX

Mar 22, 2025, 6:00 PM EDT - 9 days ago

2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio

AAPL BLK CNQ MO NEE

Mar 21, 2025, 12:59 PM EDT - 10 days ago

2025 Dividend Kings: Strong Run Continues

ABBV ABM ABT ADM AWR BDX BKH

Mar 21, 2025, 8:23 AM EDT - 10 days ago

FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease

Mar 21, 2025, 6:08 AM EDT - 10 days ago

J&J plans to invest more than $55 billion in US over next four years

Mar 21, 2025, 6:00 AM EDT - 10 days ago

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

Mar 20, 2025, 8:05 PM EDT - 10 days ago

Historic Dividend Outperformance

CVX ED IBM KO NOBL SPY

Mar 20, 2025, 6:12 PM EDT - 11 days ago

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

Mar 20, 2025, 1:55 PM EDT - 11 days ago

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough

Mar 20, 2025, 8:00 AM EDT - 11 days ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

Mar 18, 2025, 8:03 AM EDT - 13 days ago

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation

Mar 16, 2025, 1:40 PM EDT - 15 days ago

Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'

KVUE

Mar 15, 2025, 5:07 AM EDT - 16 days ago

An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.

Mar 12, 2025, 1:16 PM EDT - 19 days ago

Lilly, J&J boosted spending on executive security after UnitedHealth shooting

LLY

Mar 12, 2025, 12:58 PM EDT - 19 days ago

Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs

Mar 11, 2025, 10:38 AM EDT - 20 days ago

Cramer's Mad Dash: Johnson & Johnson

Mar 10, 2025, 8:00 AM EDT - 21 days ago

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

Mar 8, 2025, 9:00 AM EST - 23 days ago

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

Mar 7, 2025, 9:34 AM EST - 24 days ago

Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors

PFE

Mar 6, 2025, 5:28 PM EST - 25 days ago

J&J to stop late-stage study of add-on depression drug

Mar 6, 2025, 7:00 AM EST - 25 days ago

10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil

CLX DEO FTS HRL KMB MO NVS

Mar 5, 2025, 4:30 PM EST - 26 days ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 5, 2025, 1:31 PM EST - 26 days ago

5 Big Biopharmaceutical Stocks That Are Finding Favor

ABBV AMGN GILD LLY

Mar 4, 2025, 4:15 PM EST - 27 days ago

Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

Mar 4, 2025, 3:15 PM EST - 27 days ago

Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)

Mar 4, 2025, 2:56 PM EST - 27 days ago

Dogs Of The Dow Chase A "Safer" Buy For March

AMGN AMZN BA CAT CRM CSCO CVX

Mar 1, 2025, 8:00 AM EST - 4 weeks ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Upto 8% (March 2025)

ACN ADM ADP ARCC AVGO BTI CI

Feb 28, 2025, 8:01 AM EST - 4 weeks ago

Johnson & Johnson's DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

Feb 27, 2025, 2:53 AM EST - 4 weeks ago

FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled

BNTX MRNA PFE

Feb 25, 2025, 12:54 PM EST - 4 weeks ago

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

ITCI

Feb 24, 2025, 5:33 PM EST - 5 weeks ago

J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

Feb 21, 2025, 6:27 PM EST - 5 weeks ago

Final Trade: TEVA, JNJ, TJX, BABA

TEVA TJX BABA

Feb 21, 2025, 7:00 AM EST - 5 weeks ago

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Feb 21, 2025, 6:44 AM EST - 5 weeks ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

ALVO TEVA

Feb 19, 2025, 12:26 PM EST - 5 weeks ago

AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant

ABBV

Feb 18, 2025, 6:20 PM EST - 5 weeks ago

Fast Money: CELH, SLV, EEM, JNJ

EEM CELH SLV

Feb 18, 2025, 6:05 AM EST - 5 weeks ago

J&J begins crucial battle over $10 billion baby powder settlement

Feb 18, 2025, 2:25 AM EST - 5 weeks ago

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

GMAB

Feb 18, 2025, 2:16 AM EST - 5 weeks ago

Johnson & Johnson: Rich History Of Excellence Poised To Endure

Feb 15, 2025, 12:00 AM EST - 6 weeks ago

J&J resumes US rollout of Varipulse heart device after investigation